title: Investigational therapies currently in Phase II clinical trials for the treatment of pelvic serous carcinomas.
abstract: BACKGROUND
  Pelvic serous carcinomas (PSCs) are a controversial entity, which mostly comprise fallopian tube carcinoma (FTC), primary peritoneal carcinoma (PPC) and serous ovarian carcinoma (OC). Despite incremental attention towards understanding pelvic serous carcinogenesis, the gold standard treatment and survival rates have not substantially changed in these last decades.
  
  
  METHODS
  This review summarizes and gives a critical overview of the ongoing Phase II trials investigating therapies for PSC.
  
  
  CONCLUSIONS
  Several novel molecules have been developed and are currently under investigation for the treatment of PSC, including FTC, PPC and serous OC. The trend of novel targeted agents is one towards individualized, tailored therapy, based on the molecular and biological differences that characterize tumors that seem similar based solely on histological analysis. The task of developing new molecules is particularly difficult for PSC, given the recurrent development of new patterns of drug resistance. However, even if current research is focused towards identifying the best treatments for each woman with a molecularly defined disease, a deeper knowledge of the molecular biology and genetics underlying FTC and its relation as a precursor of PSC is needed.
authors: Vita-Salute San Raffaele University and IRRCS San Raffaele Hospital, Obstetrics and Gynaecology Unit , Via Olgettina 58-60, 20132, Milan , Italy.
authors: Alice
authors: A
authors: Bergamini
authors: Umberto
authors: U
authors: Leone Roberti Maggiore
authors: Simone
authors: S
authors: Ferrero
authors: Emanuela
authors: E
authors: Rabaiotti
authors: Riccardo
authors: R
authors: Viganò
authors: Micaela
authors: M
authors: Petrone
authors: Patrizia
authors: P
authors: De Marzi
authors: Stefano
authors: S
authors: Salvatore
authors: Massimo
authors: M
authors: Candiani
authors: Giorgia
authors: G
authors: Mangili
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D000077216:Carcinoma, Ovarian Epithelial; D017322:Clinical Trials, Phase II as Topic; D015195:Drug Design; D019008:Drug Resistance, Neoplasm; D015507:Drugs, Investigational / Q000494:pharmacology / Q000627:therapeutic use; D005185:Fallopian Tube Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D058990:Molecular Targeted Therapy; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy* / Q000473:pathology; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents; D015507:Drugs, Investigational
keywords: Phase II; clinical trials; epithelial ovarian cancer; fallopian tube carcinoma; therapies